Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06142383 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT06142383: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT06142383 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06142383, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Primary Outcome
Summary statistics for observed NT-proBNP values are reported: Geometric mean ratio to baseline at week 16 is calculated by the geometric mean of the ratio of the week 16 value to the baseline value. Baseline is defined as the value at randomization visit.
Interventions
- BIOLOGICAL Placebo
- DRUG Sacubitril/valsartan
- BIOLOGICAL XXB750 Low dose
- BIOLOGICAL XXB750 Medium Dose
- BIOLOGICAL XXB750 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 2 |
Why NCT06142383 stopped before completion
NCT06142383 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06142383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06142383 about?
NCT06142383 is a clinical study titled "A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure". This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
What is the current status of trial NCT06142383?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2023-12-12. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT06142383?
The interventions under investigation include: Placebo (BIOLOGICAL), Sacubitril/valsartan (DRUG), XXB750 Low dose (BIOLOGICAL), XXB750 Medium Dose (BIOLOGICAL), XXB750 High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06142383?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06142383's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI